Merck (MRK) shares down 2% following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's

November 23, 2016 7:07 AM EST

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Merck (NYSE: MRK) is recently down 2% in the premarket following Eli Lilly & Co. (LLY) failure of solanezumab data for Alzheimer's. November weekly call option implied volatility is at 15, December is at 21; compared to its 52-week range of 14 to 30.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Options, Trader Talk

Related Entities

Options, lly

Add Your Comment